Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

TAK-243 × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Classical hematology 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 87 Paclitaxel 79 Gemcitabine 73 Carboplatin 72 Surveys and Questionnaires 60 Nivolumab 53 Cisplatin 53 Bevacizumab 53 Docetaxel 52 Magnetic Resonance Spectroscopy 46 Blood Specimen Collection 45 Fluorouracil 44 Capecitabine 44 Radiotherapy 41 Irinotecan 36 Oxaliplatin 34 Erlotinib Hydrochloride 34 Biopsy 34 Specimen Handling 31 Leucovorin 31 Standard of Care 30 Pemetrexed 30 atezolizumab 28 Trastuzumab 28 Radiosurgery 27 Cetuximab 26 Sorafenib 25 Everolimus 25 Cyclophosphamide 25 Ipilimumab 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06223542 2025-09-29

Studying TAK-243 in Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡